PLX · AMEX
Protalix BioTherapeutics (PLX) Stock Price & Fundamentals
Protalix BioTherapeutics (PLX) closed at $593.32 on Oct 9, 2026, down 0.65% from the previous close of $597.21.
Share price, past year
1Y +23.44%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $593.32 |
| Sep 30, 2026 | $579.45 |
| Aug 31, 2026 | $559.95 |
| Jul 31, 2026 | $586.20 |
| Jun 30, 2026 | $555.25 |
| May 29, 2026 | $543.20 |
| Apr 30, 2026 | $532.28 |
| Mar 31, 2026 | $556.05 |
| Feb 27, 2026 | $541.21 |
| Jan 30, 2026 | $534.83 |
| Dec 31, 2025 | $517.16 |
| Nov 28, 2025 | $502.02 |
| Oct 31, 2025 | $492.56 |
Key statistics
- Market cap
- $47.72B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $80.62M
- Net income (TTM)
- $18.95M
- Shares outstanding
- 80.4M
- Dividend yield
- —
- 52-week range
- $480.65 – $597.21
Protalix BioTherapeutics's market cap is $47.72B, based on a share price of $593.32 and 80.4M shares outstanding as of Dec 31, 2025.
Financials
Protalix BioTherapeutics reported revenue of $52.74M for fiscal 2025, down 1.23% from fiscal 2024.
Protalix BioTherapeutics reported a net loss of $6.60M in fiscal 2025.
Protalix BioTherapeutics's fiscal 2025 net loss was its first in at least 3 years.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $52.74M | −1.2% | −$6.60M | −12.5% | −$0.08 | −$13.63M |
| FY2024ended Dec 31, 2024 | $53.40M | −18.5% | $2.93M | 5.5% | $0.04 | $7.39M |
| FY2023ended Dec 31, 2023 | $65.49M | +37.5% | $8.31M | 12.7% | $0.09 | −$2.47M |
| FY2022ended Dec 31, 2022 | $47.64M | +24.2% | −$14.93M | −31.3% | −$0.31 | −$25.63M |
| FY2021ended Dec 31, 2021 | $38.35M | −39.0% | −$27.58M | −71.9% | −$0.62 | −$11.74M |
| FY2020ended Dec 31, 2020 | $62.90M | +15.0% | −$6.52M | −10.4% | −$0.22 | −$26.76M |
| FY2019ended Dec 31, 2019 | $54.69M | +59.7% | −$18.28M | −33.4% | −$1.23 | −$19.99M |
| FY2018ended Dec 31, 2018 | $34.24M | +62.4% | −$26.46M | −77.3% | — | −$8.43M |
| FY2017ended Dec 31, 2017 | $21.08M | +129.1% | −$83.44M | −395.9% | — | −$10.97M |
| FY2016ended Dec 31, 2016 | $9.20M | — | −$29.37M | −319.2% | — | −$32.95M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $19.90M | $3.78M | $0.05 |
| Q1 FY2026ended Mar 31, 2026 | $33.75M | $18.32M | $0.22 |
| Q4 FY2025ended Dec 31, 2025 | $9.12M | −$5.50M | — |
| Q3 FY2025ended Sep 30, 2025 | $17.85M | $2.36M | $0.03 |
| Q2 FY2025ended Jun 30, 2025 | $15.66M | $164.00K | $0.00 |
| Q1 FY2025ended Mar 31, 2025 | $10.11M | −$3.62M | −$0.05 |
| Q4 FY2024ended Dec 31, 2024 | $18.22M | $6.49M | — |
| Q3 FY2024ended Sep 30, 2024 | $17.96M | $3.24M | $0.03 |
Company profile
- Name
- Protalix BioTherapeutics, Inc.
- Ticker
- PLX
- Exchange
- AMEX
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 2 University Plaza, Suite 100, Hackensack, NJ 07601
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001006281
Recent SEC filings
- Aug 12, 2026
- Aug 12, 2026
- Jun 25, 2026
- May 21, 2026
- May 13, 2026
- May 13, 2026
- Mar 18, 2026
- Mar 18, 2026
Frequently asked questions
What is Protalix BioTherapeutics's stock price?
Protalix BioTherapeutics (PLX) closed at $593.32 on Oct 9, 2026, down 0.65% from the previous close of $597.21.
What is Protalix BioTherapeutics's market cap?
Protalix BioTherapeutics's market cap is $47.72B, based on a share price of $593.32 and 80.4M shares outstanding as of Dec 31, 2025.
How much revenue does Protalix BioTherapeutics make?
Protalix BioTherapeutics reported revenue of $52.74M for fiscal 2025, down 1.23% from fiscal 2024.
Does Protalix BioTherapeutics pay a dividend?
Protalix BioTherapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Protalix BioTherapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures